BACKGROUND AND PURPOSE: Ancrod, derived from Malayan pit viper venom, has been tested as ischemic stroke treatment in clinical trials with inconsistent results. We studied the actions of ancrod on fibrinolysis pathways in patient plasma samples and endothelial cell culture systems. METHODS: We analyzed fibrinogen levels during the first 6 hours of ancrod infusion in patients entered in the Stroke Treatment with Ancrod Trial. For the in vitro study, human brain microvascular endothelial cells incubated with plasminogen or with human brain microvascular endothelial cell-conditioned medium were co-incubated with ancrod and fibrinogen under normal or oxygen-glucose deprivation conditions over 6 hours. RESULTS: Fibrinogen levels decreased both in vivo and in vitro. Ancrod generated fibrinopeptide A, caused visible clot formation, and reduced levels of tissue-type plasminogen activator antigen in the human brain microvascular endothelial cell system and in a cell-free system with conditioned media. CONCLUSIONS: The in vitro results indicate that ancrod causes local fibrin formation and secondary depletion of tissue-type plasminogen activator by binding to fibrin clot. Ancrod-induced fibrin formation could result in cerebral microvascular occlusion and may explain the suboptimal clinical effects of ancrod in human stroke trials.
BACKGROUND AND PURPOSE: Ancrod, derived from Malayan pit viper venom, has been tested as ischemic stroke treatment in clinical trials with inconsistent results. We studied the actions of ancrod on fibrinolysis pathways in patient plasma samples and endothelial cell culture systems. METHODS: We analyzed fibrinogen levels during the first 6 hours of ancrod infusion in patients entered in the Stroke Treatment with Ancrod Trial. For the in vitro study, human brain microvascular endothelial cells incubated with plasminogen or with human brain microvascular endothelial cell-conditioned medium were co-incubated with ancrod and fibrinogen under normal or oxygen-glucose deprivation conditions over 6 hours. RESULTS:Fibrinogen levels decreased both in vivo and in vitro. Ancrod generated fibrinopeptide A, caused visible clot formation, and reduced levels of tissue-type plasminogen activator antigen in the human brain microvascular endothelial cell system and in a cell-free system with conditioned media. CONCLUSIONS: The in vitro results indicate that ancrod causes local fibrin formation and secondary depletion of tissue-type plasminogen activator by binding to fibrin clot. Ancrod-induced fibrin formation could result in cerebral microvascular occlusion and may explain the suboptimal clinical effects of ancrod in humanstroke trials.
Authors: C E Dempfle; S Argiriou; S Alesci; K Kucher; H Müller-Peltzer; K Rübsamen; D L Heene Journal: Ann N Y Acad Sci Date: 2001 Impact factor: 5.691
Authors: Michael G Hennerici; Richard Kay; Julien Bogousslavsky; Gian Luigi Lenzi; Marc Verstraete; Jean Marc Orgogozo Journal: Lancet Date: 2006-11-25 Impact factor: 79.321
Authors: David E Levy; Gregory J del Zoppo; Bart M Demaerschalk; Andrew M Demchuk; Hans-Christoph Diener; George Howard; Markku Kaste; Arthur M Pancioli; E Bernd Ringelstein; Carmen Spatareanu; Warren W Wasiewski Journal: Stroke Date: 2009-10-29 Impact factor: 7.914
Authors: Axel Montagne; Angeliki M Nikolakopoulou; Zhen Zhao; Abhay P Sagare; Gabriel Si; Divna Lazic; Samuel R Barnes; Madelaine Daianu; Anita Ramanathan; Ariel Go; Erica J Lawson; Yaoming Wang; William J Mack; Paul M Thompson; Julie A Schneider; Jobin Varkey; Ralf Langen; Eric Mullins; Russell E Jacobs; Berislav V Zlokovic Journal: Nat Med Date: 2018-02-05 Impact factor: 53.440
Authors: Trang T Vu; Alan R Stafford; Beverly A Leslie; Paul Y Kim; James C Fredenburgh; Jeffrey I Weitz Journal: J Biol Chem Date: 2013-04-23 Impact factor: 5.157
Authors: Majd Mohammad; Manli Na; Zhicheng Hu; Minh-Thu Nguyen; Pradeep Kumar Kopparapu; Anders Jarneborn; Anna Karlsson; Abukar Ali; Rille Pullerits; Friedrich Götz; Tao Jin Journal: Commun Biol Date: 2021-03-30